Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : Crestor to be divested to Grunenthal in Europe

12/02/2020 | 09:29am EST

AstraZeneca has agreed to sell the rights to Crestor (rosuvastatin) and associated medicines in over 30 countries in Europe, except the UK and Spain, to Grunenthal GmbH (Grunenthal).

Crestor is a statin approved for the treatment of dyslipidaemia and hypercholesterolaemia.

Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, said: 'This agreement supports the management of our mature medicines to enable reinvestment into the pipeline and bringing new, innovative treatments to patients. Grunenthal previously acquired the rights to several established AstraZeneca medicines and is well placed to ensure continued access to Crestor for patients across Europe.'

AstraZeneca will continue to manufacture and supply Crestor to Grunenthal during a transition period. AstraZeneca will also continue selling the medicine in other countries, including those in North America, in Japan, China and other emerging markets.

Financial considerations

The divestment is anticipated to close in the first quarter of 2021, subject to customary closing conditions and regulatory clearances, upon which Grunenthal will make an upfront, non-contingent payment to AstraZeneca of $320m and may also make future milestone payments of up to $30m. Income arising from the upfront and future payments will be reported in AstraZeneca's financial statements within Other Operating Income & Expense. The divestment will not impact the Company's financial guidance for 2020.

Pursuant to London Stock Exchange listing rule 10.4.1R (notification of class 2 transactions), the gross book value of assets subject to the divestment as of 31 December 2019 was nil. In 2019, Crestor generated Product Sales of $136m and Profit before Tax of $98m in the countries covered by the agreement. The consideration will be paid in cash and the proceeds used for general corporate purposes.


Crestor (rosuvastatin) is a statin, a lipid-lowering medicine, used to treat blood lipid disorders and to prevent cardiovascular events, such as heart attacks and strokes. Crestor produces its lipid modifying effects in two ways: it blocks an enzyme in the liver causing the liver to make less cholesterol, and it increases the uptake and breakdown by the liver of cholesterol already in the blood. Crestor is approved as a lipid regulating medicine in more than 100 countries.


AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.


Gonzalo Vina

Tel: +44 203 749 5916

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about ASTRAZENECA PLC
01/27ASTRAZENECA : COVID-19 Vaccine Production Unaffected After Suspicious Package 'M..
01/27ASTRAZENECA : EU Asks AstraZeneca to Source COVID-19 Doses from British Plants
01/27ASTRAZENECA : COVID-19 Vaccine Wins Emergency Use Approval In Philippines
01/27ASTRAZENECA ALERT : Bragar Eagel & Squire, P.C. Announces That a Class Action La..
01/27PFIZER : Tensions rise as AstraZeneca, EU spar over vaccine delays
01/27GLANCY PRONGAY & MURRAY LLP : a Leading Securities Fraud Law Firm, Announces Inv..
01/27ASTRAZENECA : Morocco to start vaccinations on Thursday, palace says
01/27EU Clashes With AstraZeneca Over Covid-19 Vaccine Shortfall
01/27EU health official blasts slow vaccine delivery, and is consulting with Canad..
01/27Do we need to sanction each other? German minister asks after Blinken call
More news
Financials (USD)
Sales 2020 26 378 M - -
Net income 2020 2 951 M - -
Net Debt 2020 13 468 M - -
P/E ratio 2020 42,5x
Yield 2020 2,65%
Capitalization 140 B 140 B -
EV / Sales 2020 5,80x
EV / Sales 2021 4,98x
Nbr of Employees 70 600
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Average target price 127,03 $
Last Close Price 106,32 $
Spread / Highest target 47,8%
Spread / Average Target 19,5%
Spread / Lowest Target -15,1%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON6.67%448 796
ROCHE HOLDING AG4.51%312 213
NOVARTIS AG0.81%214 457
PFIZER INC.-1.55%207 384
MERCK & CO., INC.-1.89%203 035